Clarametyx Biosciences is a Columbus, Ohio-based company developing therapies and vaccines targeting the biofilm—a protective layer around bacteria— to treat chronic and recalcitrant respiratory infections. This innovative technology platform aims to disrupt biofilms to reduce biofilm-related inflammation and enable more effective immune responses and antibiotic interventions. Our first program, CMTX-101, is in a Phase 2 clinical trial to treat cystic fibrosis-associated respiratory infections.
